Pfizer Trying A Novel Oncology Business Unit To Maximize Its Novel Pipeline
This article was originally published in Pharmaceutical Approvals Monthly
With a lot of determination and a lot of licensing, Pfizer has managed to pack its oncology pipeline with novel mechanisms that show significant promise. Now the company is trying a novel business arrangement to try to make the most of what it has.
You may also be interested in...
In a move that could position Pfizer for more drastic measures down the road, the pharma giant has reorganized its development and commercial operations into several business units designed to foster autonomy and financial responsibility in the areas of specialty medicine, primary care, and emerging markets. These units join Pfizer's oncology and mature products businesses.
In Part 2 of Scrip’s roundtable, execs from Athira, Cartesian, Cyclacel, Tonix and VOZ Advisors discuss how the pandemic brought in new investors and triggered strategic shifts for the biopharma industry.
The ways companies found to move forward during the challenging year also offer opportunities for industry to improve. During a roundtable discussion with Scrip, execs from Athira, Cartesian, Cyclacel, Tonix and VOZ Advisors weighed in on the adaptations they made and what changes they’ll stick with.